Context Therapeutics Reported FY23 EPS Loss of $(1.50) Vs $(0.93) YoY, Cash Balance of $14.4M
Portfolio Pulse from Benzinga Newsdesk
Context Therapeutics reported a fiscal year 2023 earnings per share (EPS) loss of $(1.50), compared to a loss of $(0.93) in the previous year. The company also reported a cash balance of $14.4 million.
March 21, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Context Therapeutics reported a wider EPS loss of $(1.50) for FY23 compared to $(0.93) last year, with a cash balance of $14.4M.
The widening of the EPS loss from $(0.93) to $(1.50) indicates a deteriorating financial performance for Context Therapeutics, which could negatively impact investor sentiment and the stock price in the short term. The cash balance of $14.4M provides some liquidity, but the increased loss may raise concerns about future funding and operational sustainability.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100